CD19 CAR CB-NK Cells for Relapsed Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a limited number of effective treatment options for patients who relapse after CD19-targeted therapy, particularly for those with CD19-positive or CD19-negative relapsed cancer.
Innovation Solution
Administering a therapeutically effective amount of CD19-CAR+ viable cord blood natural killer (CB-NK) cells to patients with a history of anti-CD19 therapy, including those who have failed multiple prior lines of systemic therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD19-targeted CAR T-cell therapy is administered to treat cancer, then complete remission can be achieved in 40-90% of patients, but 30-60% of patients relapse after treatment
Solution Approach 1:
The patent changes the cell type parameter from T-cells to NK cells while maintaining the CD19 CAR targeting. This parameter change enables the therapy to work through different mechanisms (innate immune receptor-mediated killing vs. adaptive immune recognition), thereby achieving remission in relapsed patients who failed CD19 CAR T-cell therapy.
2Reliability
If CD19 CAR T-cell therapy is used to treat cancer, then effective treatment can be achieved, but eligible treatment options for post-CAR relapse are limited
Solution Approach 1:
The CD19 CAR NK cells serve multiple functions: they can treat both CD19-positive relapsed cancer through CAR-mediated recognition and CD19-negative relapsed cancer through innate immune receptor-mediated killing. This multi-functionality expands treatment options for relapsed patients who have exhausted CD19-targeted CAR T-cell therapy.
3Reliability
If CD19-CAR+ viable CB-NK cells are administered at higher doses to improve treatment efficacy, then therapeutic effect may be enhanced, but cell product complexity and manufacturing requirements increase
Solution Approach 1:
The patent uses cord blood-derived NK cells instead of T-cells, which changes the biological parameters of the cell product. CB-NK cells have different proliferation kinetics, persistence characteristics, and manufacturing requirements compared to CAR T-cells, potentially simplifying some aspects of product complexity while enabling treatment of relapsed patients.
Data Source
AI summary
The present disclosure provides, among other things methods and compositions for the treatment of cancer comprising administering CD19 CAR cord blood derived natural killer (CB-NK) cells to a patient in need thereof.